Perioperative treatment for untreated stage II head and neck cancer
Part of Cancer clinical trials.
This trial tests a new combination of a drug called finotonlimab (a type of immunotherapy that helps your immune system fight cancer) with chemotherapy for patients with stage II head and neck cancer that has not been treated yet. The treatment is given before and after surgery to see if it can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with head and neck squamous cell carcinoma (a type of cancer) that has not spread to other parts of the body and can be removed with surgery.
- You have not had prior radiation, chemotherapy, immunotherapy, or other biological treatments for this cancer.
- You are willing to have surgery as part of your treatment.
- Your major organs (like blood, liver, and kidneys) are functioning well enough to receive the study treatment.
- You are not pregnant or breastfeeding and are willing to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two immunotherapy drugs (ivonescimab vs. pembrolizumab) given before and after surgery for head and neck cancer that can be surgically removed. The goal is to see which drug works better to shrink the tumor and prevent the cancer from coming back.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.